The Pharmacy Times® Cholangiocarcinoma Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of cholangiocarcinoma.
December 11th 2024
PLT012 demonstrates its potential against multiple tumors with unmet medical needs.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
FDA Grants Accelerated Approval to Futibatinib for Locally Advanced, Metastatic Cholangiocarcinoma
October 3rd 2022Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.
Read More
NDA Submitted to FDA for Ivosidenib for Previously Treated IDH1-Mutated Cholangiocarcinoma
March 2nd 2021A supplemental new drug application has been submitted to the FDA for ivosidenib tablets (Tibsovo) as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.
Read More
Pemigatinib Approved by FDA as First Targeted Treatment for Patients With Cholangiocarcinoma
April 18th 2020The FDA has granted accelerated approval to pemigatinib (Pemazyre, Incyte Corporation) as the first treatment for adults with certain types of previously treated, advanced cholangiocarcinoma.
Read More